Dr. Martin Lerner


“The myocardial dynamics of these patients was frightening”

Among others Dr. Lerner was the Chief of the Division of Infectious Diseases and established a virology laboratory at Wayne State University School of Medicine.

Dr. Martin

Dr .Martin Lerner came down with ME/CFS and has spent the latter half of his career treating and researching it.

Dr. Martin Lerner became acquainted  with Chronic Fatigue Syndrome in a very direct way: he caught it in 1988 and was invalided by it until 1996.  One of three Infectious Disease Specialists focusing on ME/CFS (w/Dr. Chia, Dr. Montoya) in the United States, Dr. Lerner’s focus on and treatment of herpesviruses has left an indelible footprint on this field.

His studies and papers over the past fifteen years have kept the herpesvirus infection hypothesis of ME/CFS alive and his treatment approach has been cited by and posted on Dr. Montoya’s Stanford website. Dr. Lerner pioneered the Holter Monitor test as a diagnostic tool for Chronic Fatigue Syndrome and created and validated the Energy Point Index to monitor functionality. He believes a defective form of Epstein-Barr Virus may be play a key role in ME/CFS. The Glazer/Williams group is exploring this theory.

Dr. Lerner is on Health Rising’s Ask an ME/CFS Expert Monthly Panel.

Documents and Video’s

Blogs and Interviews


A. Martin Lerner, M.D., M.A.C.P
32804 Pierce Road
Beverly Hills, MI 48025 

Telephone: (248) 540-9866
Fax: (248) 540-0139
Email: Dr. Lerner


Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset. Lerner AM, Ariza ME, Williams M, Jason L, Beqaj S, Fitzgerald JT, Lemeshow S, Glaser R. PLoS One. 2012;7(11):e47891. doi: 10.1371/journal.pone.0047891. Epub 2012 Nov 14.

Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. In Vivo. 2007 Sep-Oct;21(5):707-13.

Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome. Lerner AM, Dworkin HJ, Sayyed T, Chang CH, Fitzgerald JT, Beqaj S, Deeter RG, Goldstein J, Gottipolu P, O’Neill W. In Vivo. 2004 Jul-Aug;18(4):417-24.

IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. In Vivo. 2004 Mar-Apr;18(2):101-6.

A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O’Neill W. Drugs Today (Barc). 2002 Aug;38(8):549-61. Review.

IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT.

A small, randomized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Lerner AM, Zervos M, Chang CH, Beqaj S, Goldstein J, O’Neill W, Dworkin H, Fitgerald T, Deeter RG. Clin Infect Dis. 2001 Jun 1;32(11):1657-8. No abstract available.

Abnormal left ventricular myocardial dynamics in eleven patients with chronic fatigue syndrome. Dworkin HJ, Lawrie C, Bohdiewicz P, Lerner AM. Clin Nucl Med. 1994 Aug;19(8):675-7.

A new continuing fatigue syndrome following mild viral illness. A proscription to exercise. Lerner AM. Chest. 1988 Nov;94(5):901-2. No abstract available.

Share This